Tyra Biosciences (NASDAQ:TYRA) Director Sells $250,000.00 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Robert More sold 10,000 shares of Tyra Biosciences stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director owned 3,823,425 shares in the company, valued at $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock traded up $2.52 on Friday, hitting $25.51. 2,092,508 shares of the company’s stock traded hands, compared to its average volume of 499,165. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $25.88. The firm’s 50-day moving average is $18.17 and its 200 day moving average is $13.66.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). On average, analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Tyra Biosciences

A number of large investors have recently modified their holdings of the company. Swiss National Bank lifted its position in Tyra Biosciences by 42.0% in the 1st quarter. Swiss National Bank now owns 29,400 shares of the company’s stock valued at $273,000 after purchasing an additional 8,700 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Tyra Biosciences in the first quarter valued at approximately $465,000. American Century Companies Inc. raised its holdings in shares of Tyra Biosciences by 5.8% during the first quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock valued at $218,000 after buying an additional 1,289 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Tyra Biosciences by 9.7% during the first quarter. Wellington Management Group LLP now owns 104,087 shares of the company’s stock worth $968,000 after buying an additional 9,228 shares during the period. Finally, AlphaQuest LLC grew its holdings in Tyra Biosciences by 489.7% in the 1st quarter. AlphaQuest LLC now owns 29,622 shares of the company’s stock worth $275,000 after buying an additional 24,599 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TYRA. Wedbush boosted their price objective on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Raymond James Financial assumed coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a research note on Wednesday, September 10th. Finally, Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.17.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.